DB:9SO

Stock Analysis Report

Executive Summary

Solasia Pharma K.K. develops drugs in the field of oncology in Asia.


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Solasia Pharma K.K's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 9SO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-19.7%

9SO

-11.1%

DE Biotechs

-9.1%

DE Market


1 Year Return

-40.0%

9SO

-2.9%

DE Biotechs

2.9%

DE Market

Return vs Industry: 9SO underperformed the German Biotechs industry which returned -2.9% over the past year.

Return vs Market: 9SO underperformed the German Market which returned 2.9% over the past year.


Shareholder returns

9SOIndustryMarket
7 Day-19.7%-11.1%-9.1%
30 Day-27.1%-12.8%-7.2%
90 Day-17.1%-9.6%-6.5%
1 Year-40.0%-40.0%-2.7%-2.9%6.1%2.9%
3 Yearn/a25.8%24.4%3.5%-5.6%
5 Yearn/a1.6%-0.5%8.0%-6.8%

Price Volatility Vs. Market

How volatile is Solasia Pharma K.K's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Solasia Pharma K.K undervalued compared to its fair value and its price relative to the market?

2.07x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 9SO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 9SO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 9SO is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 9SO is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 9SO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 9SO is good value based on its PB Ratio (2.3x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Solasia Pharma K.K forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Solasia Pharma K.K has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Solasia Pharma K.K performed over the past 5 years?

-27.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 9SO is currently unprofitable.

Growing Profit Margin: 9SO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 9SO is unprofitable, and losses have increased over the past 5 years at a rate of -27.3% per year.

Accelerating Growth: Unable to compare 9SO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 9SO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 9SO has a negative Return on Equity (-26.99%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Solasia Pharma K.K's financial position?


Financial Position Analysis

Short Term Liabilities: 9SO's short term assets (¥4.3B) exceed its short term liabilities (¥925.0M).

Long Term Liabilities: 9SO's short term assets (¥4.3B) exceed its long term liabilities (¥104.0M).


Debt to Equity History and Analysis

Debt Level: 9SO is debt free.

Reducing Debt: 9SO has no debt compared to 5 years ago when its debt to equity ratio was 519.6%.


Balance Sheet

Inventory Level: 9SO has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 9SO's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 9SO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 9SO has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of -23.2% each year.


Next Steps

Dividend

What is Solasia Pharma K.K's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.9%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 9SO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 9SO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 9SO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 9SO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 9SO's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.2yrs

Average board tenure


CEO

Yoshihiro Arai (59yo)

6.9yrs

Tenure

0

Mr. Yoshihiro Arai has been the President and Representative Director at Solasia Pharma KK since February 2013. Mr. Arai served as Executive Vice President of Development of JapanBridge, Inc. since Septemb ...


Board Members

NamePositionTenureCompensationOwnership
Yoshihiro Arai
President and Representative Director6.9yrsno data0.46% ¥555.7k
Toshio Miyashita
Chief Financial Officer4.2yrsno data0.37% ¥438.8k
Masahiro Michisuji
External Director11.8yrsno data0.072% ¥86.3k
Makoto Matsuo
External Corporate Auditor0yrsno datano data
Stanley Lau
External Director0yrsno datano data
Norikazu Eiki
External Director3.8yrsno datano data
Yasuhiro Abe
External Director0yrsno datano data
Koichi Sagiya
Full-Time External Corporate Auditor0yrsno datano data
Tasuku Toita
External Corporate Auditor0yrsno datano data
Susumu Araki
Statutory Auditor1.1yrsno datano data

4.2yrs

Average Tenure

65yo

Average Age

Experienced Board: 9SO's board of directors are considered experienced (4.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.8%.


Top Shareholders

Company Information

Solasia Pharma K.K.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Solasia Pharma K.K.
  • Ticker: 9SO
  • Exchange: DB
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: JP¥14.317b
  • Listing Market Cap: JP¥120.166m
  • Shares outstanding: 116.40m
  • Website: https://www.solasia.co.jp

Number of Employees


Location

  • Solasia Pharma K.K.
  • Sumitomo Fudosan Shiba-Koen Tower
  • 4th Floor
  • Tokyo
  • 105-0011
  • Japan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4597TSE (The Tokyo Stock Exchange)YesCommon SharesJPJPYMar 2017
9SODB (Deutsche Boerse AG)YesCommon SharesDEEURMar 2017

Biography

Solasia Pharma K.K. develops drugs in the field of oncology in Asia. The company offers episil oral liquid for the control and relief of pain; and Sancuso, a transdermal delivery system that delivers granisetron, an anti-emetic into the patient’s bloodstream for the treatment of chemotherapy induced nausea and vomiting. It is also developing SP-02, a mitochondrial-targeted agent, which is in Phase II clinical study to treat various hematologic and solid cancers; and SP-04, which has completed phase IIb clinical trials for chemotherapy induced peripheral neuropathy. The company was founded in 2006 and is based in Tokyo, Japan. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/29 00:07
End of Day Share Price2020/02/28 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.